Celltrion, Inc.

KSE:068270.KS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

South Korea

Market Cap

USD 26.66 B

Share Price

USD 117.76

Avg Daily Volume

484,019

Change (1 day)

1.81%

Change (1 year)

-8.55%

Change (YTD)

-7.09%

Celltrion, Inc. EBIT Margin for the year ending December 31, 2024: 18.66%

Celltrion, Inc. EBIT Margin is 18.66% for the year ending December 31, 2024, a -41.32% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Celltrion, Inc. EBIT Margin for the year ending December 31, 2023 was 31.79%, a 15.88% change year over year.
Celltrion, Inc. EBIT Margin for the year ending December 31, 2022 was 27.44%, a -29.52% change year over year.
Celltrion, Inc. EBIT Margin for the year ending December 31, 2021 was 38.93%, a 8.73% change year over year.
Celltrion, Inc. EBIT Margin for the year ending December 31, 2020 was 35.80%, a 5.90% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBIT Margin	EBITDA Margin	Net Income Margin	EBT Margin

KSE: 068270.KS

Celltrion, Inc.

CEO	Mr. Hyong-Gi Kim
IPO Date	July 19, 2005
Location	South Korea
Headquarters	23 Academy-ro
Employees	2,391
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.